Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316802 | 0.84 | MAP4K4 (0.42) | ADORA1MAPTADORA2AMEN1KMT2A | |
| SCHEMBL6322895 | 0.83 | SMN1; SMN2 (0.42) | ADORA1ADORA2AGAATACR3SMN1; SMN2 | |
| SCHEMBL6322010 | 0.82 | ADORA1 (0.41) | ADORA1MAPTTSHRMEN1KMT2A | |
| SCHEMBL6318046 | 0.81 | ADORA1 (0.42) | ADORA1TSHRADORA2AMEN1KMT2A | |
| SCHEMBL6318523 | 0.81 | ADORA1 (0.38) | ADORA1MAPTADORA2AMEN1KMT2A | |
| SCHEMBL6315987 | 0.78 | NPC1 (0.47) | ADORA1ADORA2ATACR3SMN1; SMN2NPC1 | |
| SCHEMBL6319257 | 0.78 | ALDH1A1 (0.39) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL6321948 | 0.78 | RAB9A (0.55) | ADORA1MAPTTSHRADORA2AGAA | |
| SCHEMBL6315246 | 0.76 | KDM4E (0.53) | ADORA1MAPTTSHRADORA2AMEN1 | |
| SCHEMBL6317601 | 0.75 | NPC1 (0.42) | MAPTTSHRMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | ADORA1 1592/4885MAPT 281/4885TSHR 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.